UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Blood, 2017-03, Vol.129 (12), p.1658-1668

2017

Link zum Volltext

Verfügbarkeit prüfen

Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia

Clinical infectious diseases, 2020-06, Vol.71 (1), p.63-71

2020

Link zum Volltext

Verfügbarkeit prüfen

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Blood advances, 2019-03, Vol.3 (6), p.851-861

2019

Link zum Volltext

Verfügbarkeit prüfen

8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms

Leukemia research, 2018-03, Vol.66, p.73-78

2018

Link zum Volltext

Verfügbarkeit prüfen

Myeloid disorders after autoimmune disease

Best practice & research. Clinical haematology, 2019-03, Vol.32 (1), p.74-88

2019

Link zum Volltext

Verfügbarkeit prüfen

Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase

Communications biology, 2021-10, Vol.4 (1), p.1184-9, Article 1184

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular pathogenesis of acquired aplastic anemia

European journal of haematology, 2019-02, Vol.102 (2), p.103-110

2019

Link zum Volltext

Verfügbarkeit prüfen

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes

Cancer, 2019-04, Vol.125 (7), p.1091-1100

2019

Link zum Volltext

Verfügbarkeit prüfen

The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia

Blood reviews, 2020-09, Vol.43, p.100650-100650, Article 100650

2020

Link zum Volltext

Verfügbarkeit prüfen

PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation

The American journal of pathology, 2015-05, Vol.185 (5), p.1396-1408

2015

Link zum Volltext

Verfügbarkeit prüfen

The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia

Blood reviews, 2020-03, Vol.40, p.100639-100639, Article 100639

2020

Link zum Volltext

Verfügbarkeit prüfen

Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape

Molecular cell, 2024-04, Vol.84 (8), p.1475-1495.e18

2024

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies

Cancer, 2023-02, Vol.129 (4), p.580-589

2023

Link zum Volltext

Verfügbarkeit prüfen

Leukemic Involvement in the Thorax

Radiographics, 2019-01, Vol.39 (1), p.44

2019

Link zum Volltext

Verfügbarkeit prüfen

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

Cancer, 2019-06, Vol.125 (11), p.1855-1866

2019

Link zum Volltext

Verfügbarkeit prüfen

What are the most promising new agents in myelodysplastic syndromes?

Current opinion in hematology, 2019-03, Vol.26 (2), p.77

2019

Link zum Volltext

Verfügbarkeit prüfen

Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia

Expert review of anticancer therapy, 2019-08, Vol.19 (8), p.717-729

2019

Link zum Volltext

Verfügbarkeit prüfen

A multimodality work‐up of patients with Hypereosinophilia

American journal of hematology, 2018-11, Vol.93 (11), p.1337-1346

2018

Link zum Volltext

Verfügbarkeit prüfen

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

The Lancet. Haematology, 2020-08, Vol.7 (8), p.e601-e612

2020

Link zum Volltext

Verfügbarkeit prüfen

Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Blood, 2020-11, Vol.136 (Supplement 1), p.15-15

2020

Link zum Volltext

Verfügbarkeit prüfen

Outcomes with lower intensity therapy in TP53-mutated AML

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7017-7017

2017

Link zum Volltext

Verfügbarkeit prüfen

JAK2 Variants Associated with Secondary-AML from MPN

Blood, 2017-12, Vol.130, p.305-305

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(30)
Berichte
(1)

Sprache

Englisch
(31)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(17)
Hematology
(12)
Acute Myeloid Leukemia
(8)
Adult
(8)
Female
(8)
Male
(8)
Middle Aged
(7)
Oncology
(6)
Aged
(5)
Leukemia
(5)
Mutation
(5)
Animals
(4)
Bone Marrow
(4)
Leukemia, Myeloid, Acute - Drug Therapy
(4)
Leukemia, Myeloid, Acute - Pathology
(4)
Patients
(4)
Young Adult
(4)
Adolescent
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms

Myeloid disorders after autoimmune disease

Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase

Molecular pathogenesis of acquired aplastic anemia

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes

The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia

PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation

The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia

Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape

A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies

Leukemic Involvement in the Thorax

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

What are the most promising new agents in myelodysplastic syndromes?

Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia

A multimodality work‐up of patients with Hypereosinophilia

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients

Outcomes with lower intensity therapy in TP53-mutated AML

JAK2 Variants Associated with Secondary-AML from MPN

Characteristics and Outcomes of Malignancy-Associated Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Single-Center Experience

Suchergebnisse filtern